Evogene Ltd. (NASDAQ:EVGN) Short Interest Update

Evogene Ltd. (NASDAQ:EVGN) was the target of a large increase in short interest in February. As of February 28th, there was short interest totalling 33,200 shares, an increase of 107.5% from the February 13th total of 16,000 shares. Based on an average daily trading volume, of 41,400 shares, the days-to-cover ratio is currently 0.8 days. Currently, 0.6% of the shares of the stock are sold short.

Analyst Ratings Changes

Several research analysts have issued reports on the company. StockNews.com started coverage on Evogene in a research note on Monday. They set a “sell” rating for the company. Alliance Global Partners reiterated a “buy” rating on shares of Evogene in a research report on Friday, March 7th.

Evogene Price Performance

Shares of EVGN traded up $0.05 on Friday, hitting $1.43. The company’s stock had a trading volume of 11,265 shares, compared to its average volume of 88,915. The company has a market capitalization of $7.68 million, a PE ratio of -0.32 and a beta of 1.28. Evogene has a fifty-two week low of $1.20 and a fifty-two week high of $9.00. The company has a 50 day moving average price of $1.54 and a 200 day moving average price of $2.00.

Evogene (NASDAQ:EVGN) last posted its quarterly earnings data on Thursday, March 6th. The biotechnology company reported $0.06 EPS for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.78. Evogene had a negative return on equity of 109.05% and a negative net margin of 314.43%. The company had revenue of $1.61 million for the quarter, compared to analyst estimates of $3.63 million. During the same quarter in the previous year, the firm earned ($1.30) earnings per share.

Hedge Funds Weigh In On Evogene

An institutional investor recently bought a new position in Evogene stock. Citadel Advisors LLC acquired a new position in Evogene Ltd. (NASDAQ:EVGN) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 15,891 shares of the biotechnology company’s stock, valued at approximately $30,000. Citadel Advisors LLC owned about 0.30% of Evogene at the end of the most recent reporting period. 10.40% of the stock is currently owned by hedge funds and other institutional investors.

Evogene Company Profile

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.